{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:20:07Z","timestamp":1791091207282,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1053\/j.ajkd.2007.04.025","type":"journal-article","created":{"date-parts":[[2007,8,6]],"date-time":"2007-08-06T11:06:08Z","timestamp":1186398368000},"page":"203-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"title":["Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension"],"prefix":"10.1053","volume":"50","author":[{"given":"Hassane","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rixe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Billemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Baumelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Deray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2007.04.025_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00666035","article-title":"The role of vascular endothelial growth factor in pathological angiogenesis","volume":"36","author":"Ferrara","year":"1995","journal-title":"Breast Cancer Res Treat"},{"key":"10.1053\/j.ajkd.2007.04.025_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/bcr919","article-title":"New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors","volume":"6","author":"Lin","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1053\/j.ajkd.2007.04.025_bib3","first-page":"1117","article-title":"Trastuzumab in breast cancer","volume":"18","author":"Emens","year":"2004","journal-title":"Oncology (Huntingt)"},{"key":"10.1053\/j.ajkd.2007.04.025_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/00313029309090851","article-title":"An immunohistological study of epidermal growth factor receptor and neu receptor and neu receptor expression in proliferative glomerulonephritis","volume":"25","author":"Roy-Chaudhury","year":"1993","journal-title":"Pathology"},{"key":"10.1053\/j.ajkd.2007.04.025_bib5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S0022-5347(17)39100-0","article-title":"Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma","volume":"142","author":"Sargent","year":"1989","journal-title":"J Urol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib6","first-page":"764","article-title":"Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury","volume":"9","author":"Nakopoulou","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.04.025_bib7","first-page":"189","article-title":"Identification and localization of epidermal growth factor and its receptor in the human glomerulus","volume":"63","author":"Yoshioka","year":"1990","journal-title":"Lab Invest"},{"key":"10.1053\/j.ajkd.2007.04.025_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0065-230X(08)60058-5","article-title":"Tumor angiogenesis","volume":"19","author":"Folkman","year":"1974","journal-title":"Adv Cancer Res"},{"key":"10.1053\/j.ajkd.2007.04.025_bib9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib10","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1210\/mend-5-12-1806","article-title":"The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA","volume":"5","author":"Houck","year":"1991","journal-title":"Mol Endocrinol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib11","doi-asserted-by":"crossref","first-page":"11947","DOI":"10.1016\/S0021-9258(18)99049-6","article-title":"The human gene for vascular endothelial growth factor","volume":"266","author":"Tischer","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ajkd.2007.04.025_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s001099900019","article-title":"Molecular and biological properties of vascular endothelial growth factor","volume":"77","author":"Ferrara","year":"1999","journal-title":"J Mol Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib13","doi-asserted-by":"crossref","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","article-title":"VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature","volume":"290","author":"Kamba","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2007.04.025_bib15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1097\/01.ASN.0000013925.19218.7B","article-title":"Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice","volume":"13","author":"Mattot","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib16","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1681\/ASN.V1171236","article-title":"Vascular endothelial growth factor receptors in human mesangium in vitro and in glomerular disease","volume":"11","author":"Thomas","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib17","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ajkd.2007.04.025_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1677\/erc.1.00600","article-title":"Epidermal growth factor receptor inhibition strategies in oncology","volume":"11","author":"Harari","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"10.1053\/j.ajkd.2007.04.025_bib23","unstructured":"Vidal: Herceptin (ed 82). 2006, pp 962-964. Available at: www.vidal.fr. Accessed: January 15, 2007"},{"issue":"suppl 15","key":"10.1053\/j.ajkd.2007.04.025_bib24","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2006.04.022","article-title":"Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer","volume":"33","author":"Jensen","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib25","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib26","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor","volume":"344","author":"Joensuu","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib27","first-page":"5143","article-title":"Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class","volume":"60","author":"Kilic","year":"2000","journal-title":"Cancer Res"},{"key":"10.1053\/j.ajkd.2007.04.025_bib28","first-page":"5778","article-title":"Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis","volume":"61","author":"Sjoblom","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.ajkd.2007.04.025_bib29","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2007.04.025_bib30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib31","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.ajkd.2007.04.025_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ndt\/17.4.685","article-title":"Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571","volume":"17","author":"Kitiyakara","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.04.025_bib33","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/1042819031000079140","article-title":"Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia","volume":"44","author":"Pou","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.ajkd.2007.04.025_bib34","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1053\/j.ajkd.2004.12.017","article-title":"Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: True association or mere coincidence?","volume":"45","author":"Al Aly","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.04.025_bib35","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1345\/aph.1G131","article-title":"Acute renal failure secondary to imatinib mesylate treatment in prostate cancer","volume":"39","author":"Foringer","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.ajkd.2007.04.025_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2710.2004.00543.x","article-title":"Gefitinib, a novel, orally administered agent for the treatment of cancer","volume":"29","author":"Ranson","year":"2004","journal-title":"J Clin Pharm Ther"},{"key":"10.1053\/j.ajkd.2007.04.025_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2004.04.150","article-title":"The ErbB\/HER receptor proteintyrosine kinases and cancer","volume":"319","author":"Roskoski","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2007.04.025_bib38","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.2165\/00003495-200060001-00004","article-title":"ZD1839 (\u2018Iressa\u2019) as an anticancer agent","volume":"60","author":"Baselga","year":"2000","journal-title":"Drugs"},{"key":"10.1053\/j.ajkd.2007.04.025_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/01.cad.0000127666.12215.7b","article-title":"Acute lung injury as an adverse event of gefitinib","volume":"15","author":"Inomata","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1053\/j.ajkd.2007.04.025_bib40","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1200\/JCO.2004.09.064","article-title":"Side effects of the therapy: Case 1","volume":"22","author":"Kumasaka","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00408-005-2581-0","article-title":"Acute renal failure associated with gefitinib therapy","volume":"184","author":"Wan","year":"2006","journal-title":"Lung"},{"key":"10.1053\/j.ajkd.2007.04.025_bib42","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"10.1053\/j.ajkd.2007.04.025_bib43","unstructured":"Iwata K, Provoncha K, Gibson N: Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva) [abstract 79]. Presented at the Annual Meeting of the American Society of Clinical Oncology, Orlando, 2002"},{"key":"10.1053\/j.ajkd.2007.04.025_bib44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0093-7754(03)70022-0","article-title":"Development of the epidermal growth factor receptor inhibitor OSI-774","volume":"30","author":"Grunwald","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib45","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.04.025_bib47","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib48","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: Case report and literature review","volume":"49","author":"George","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.04.025_bib50","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib52","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib53","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1200\/JCO.2005.02.0503","article-title":"Mechanisms of hypertension associated with BAY 43-9006","volume":"24","author":"Veronese","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib54","doi-asserted-by":"crossref","unstructured":"Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2005 Annual Meeting Proceedings Part I 23(16S), 2005 (June 1 Suppl) (abstr 4510)","DOI":"10.1200\/jco.2005.23.16_suppl.lba4510"},{"key":"10.1053\/j.ajkd.2007.04.025_bib55","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2007.04.025_bib56","first-page":"S380A","article-title":"AG-013736, a multitarget tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC)","volume":"23","author":"Rini","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib57","first-page":"2178","article-title":"PTK787\/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration","volume":"60","author":"Wood","year":"2000","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2007.04.025_bib58","first-page":"S1090A","article-title":"A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin\/5-fluorouracil\/leucovorin and PTK787\/ZK 222584 or placebo (CONFIRM-1)","volume":"23","author":"Hecht","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib59","doi-asserted-by":"crossref","unstructured":"Drevs J, Medinger M, Mross K, et al: Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005 Annual Meeting Proceedings Part I 23(16S), 2005 (June 1 Suppl) (abstr 3002)","DOI":"10.1200\/jco.2005.23.16_suppl.3002"},{"key":"10.1053\/j.ajkd.2007.04.025_bib60","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2005.09.034","article-title":"Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787\/ZK 222584 administered twice daily in patients with advanced cancer","volume":"23","author":"Thomas","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2006.05.055","article-title":"A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration","volume":"113","author":"Nguyen","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1053\/j.ajkd.2007.04.025_bib62","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.04.025_bib63","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1046\/j.1523-1755.2001.0590041324.x","article-title":"PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis","volume":"59","author":"Gilbert","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.04.025_bib64","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0065-2776(08)60444-7","article-title":"The immunology and pathology of NZB mice","volume":"9","author":"Howie","year":"1968","journal-title":"Adv Immunol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib65","first-page":"12","article-title":"Relevance of systemic lupus erythematosus nephritis animal models to human disease","volume":"19","author":"Foster","year":"1999","journal-title":"Semin Nephrol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1681\/ASN.2004050392","article-title":"Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice","volume":"16","author":"Lassila","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib67","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.0000202487.68969.f7","article-title":"Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2) rats","volume":"47","author":"Schellings","year":"2006","journal-title":"Hypertension"},{"key":"10.1053\/j.ajkd.2007.04.025_bib68","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1096\/fj.03-0702fje","article-title":"Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition","volume":"18","author":"Francois","year":"2004","journal-title":"FASEB J"},{"key":"10.1053\/j.ajkd.2007.04.025_bib69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10456-004-2699-3","article-title":"Angiogenic growth factors and hypertension","volume":"7","author":"Sane","year":"2004","journal-title":"Angiogenesis"},{"key":"10.1053\/j.ajkd.2007.04.025_bib70","series-title":"Pathophysiology: The Biologic Basis for Disease in Adults and Children","author":"McCance","year":"2002"},{"key":"10.1053\/j.ajkd.2007.04.025_bib71","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/01.CIR.0000061911.47710.8A","article-title":"VIVA Investigators: The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis","volume":"107","author":"Henry","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2007.04.025_bib72","doi-asserted-by":"crossref","first-page":"L344","DOI":"10.1152\/ajplung.00291.2003","article-title":"Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor","volume":"287","author":"Tang","year":"2004","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib73","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib74","first-page":"865A","article-title":"Further characterization of the potent VEGF\/PDGF receptor tyrosine kinase inhibitor AG-013736 in preclinical tumor models for its antiangiogenesis and antitumor activity","volume":"44","author":"Wickman","year":"2003","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1053\/j.ajkd.2007.04.025_bib75","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1523-1755.2005.00575.x","article-title":"VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells","volume":"68","author":"Feliers","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.04.025_bib76","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1161\/01.CIR.0000069826.36125.B4","article-title":"Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases","volume":"107","author":"Safar","year":"2003","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2007.04.025_bib77","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/cvr\/27.6.951","article-title":"Medial necrosis and acute alterations in aortic distensibility following removal of the vasa vasorum of canine ascending aorta","volume":"27","author":"Stefanadis","year":"1993","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.ajkd.2007.04.025_bib78","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0272-6386(12)81119-X","article-title":"The renal lesion of preeclampsia revisited","volume":"17","author":"Kincaid-Smith","year":"1991","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2007.04.025_bib80","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2007.04.025_bib81","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1046\/j.1523-1755.1999.00769.x","article-title":"Collapsing glomerulopathy in HIV and non-HIV patients: A clinicopathological and follow-up study","volume":"56","author":"Laurinavicius","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.04.025_bib82","doi-asserted-by":"crossref","unstructured":"Mares JE, Worah S, Mathew SV: Increased rates of hypertension (HTN) among patients with advanced carcinoma treated by bevacizumab. 41st Annual Meeting of the American Society of Clinical Oncology (ASCO), 2005 (abstr 4087)","DOI":"10.1200\/jco.2005.23.16_suppl.4087"},{"key":"10.1053\/j.ajkd.2007.04.025_bib83","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/sj.ki.5000439","article-title":"Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis","volume":"69","author":"Hara","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2007.04.025_bib84","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/17.7.1327","article-title":"Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: Differing effects of anti-proteinuric therapies","volume":"17","author":"Kelly","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2007.04.025_bib85","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.amjhyper.2005.09.022","article-title":"Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries","volume":"19","author":"Kitayama","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ajkd.2007.04.025_bib86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.ATV.0000252062.48280.61","article-title":"The vasohibin family","volume":"27","author":"Sato","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib87","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.ajkd.2007.04.025_bib88","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","article-title":"Combined analysis of efficacy: The addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638607008359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638607008359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:47:22Z","timestamp":1759456042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638607008359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0272638607008359"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2007.04.025","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiogenesis Inhibitor Therapies: Focus on Kidney Toxicity and Hypertension","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2007.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}